Archives

Infravia launches Infravia Growth Fund and welcomes Alban WynieckiI,Guillaume Santamaria and Francois auquepre

InfraVia

A growth fund dedicated to tech and supporting the digitalization of infrastructure and the economy

Leveraging its experience and capabilities in infrastructure investments, InfraVia Capital Partners (“InfraVia”) announces the launch of InfraVia Growth Fund. While digital transformation is impacting the whole economy, including infrastructure, and brings infrastructure closer to the services economy, InfraVia intends to support tech companies at scale-up stage.

Established in 2008, InfraVia currently manages 4 infrastructure funds totaling €4bn of AUM and has invested in over 30 companies across Europe. A pioneer in European infrastructure, InfraVia was amongst the first investors in digital infrastructure such as data centers, fiber networks or telecom towers. Thanks to its deep knowledge of the ecosystem, InfraVia is launching a second business line focusing on growth investments with the aim to support tech companies that experience strong growth. “Our experience and skills are great assets to identify, assess and accelerate scale-up companies”said Vincent LEVITA, founder and CEO of InfraVia.

Like it does in most sectors, digital is disrupting infrastructure business models and usage. Digital tools and big data help reduce costs, improve efficiency, reduce risks and enable infrastructure assets to optimize their performance and converge towards the services economy. “Combining physical assets that are key for the economy and new technologies will lead to unprecedented opportunities in terms of growth and performance”,added Vincent Levita.

In order to support and benefit from this structural shift, InfraVia announces the launch of a fund dedicated to leading tech companies operating in sectors in which it has historically invested, such as mobility, logistics, telecom, utility, health and energy. “The sesectors are all affected by deep changes linked notably to the rise of new digital players who need significant capital to remain competitive on a global basis. We intend to help them, not only with funding but also through long-term operational support”Guillaume Santamaria, Partner InfraVia, commented
Targeting a size of €300m, with capital expected to come mostly from its existing institu-tional investors, InfraVia has the ambition to become a leading growth investor with theaim to support, accelerate and internationalize European fast-growing tech companies.The fund will focus on companies that have high growth potential and that are either profitable or nearing profitability.
To achieve its ambition in growth capital, InfraVia is building a dedicated team of seasoned professionals with solid backgrounds in technology, investment and the industrial sector.This 10-strong team will be led by its 3 partners: Alban Wyniecki, Guillaume Santamaria and François Auque.
“Guillaume, François and I are excited to leverage our joint experience (more than 50 deals in the past 5 years) to support and back tomorrow’s tech leaders, and we are veryhappy to join InfraVia’s partnership to deliver on that ambition”Alban Wyniecki, Partner InfraVia, added.
As underpinned in the recent Tibi report, only few French tech companies grow global and make it to the IPO stage, often by lack of sufficient late-stage funding. The French government recently formally showed its support to growth companies and called for French institutional investors to pledge significant capital to start-ups and scale-ups.The InfraVia Growth fund is precisely looking to capture part of this market opportunity. “Institutional investors are ready to support our initiative to back emerging champions in the tech space” François Auque, Partner InfraVia, commented. It is vital for France’s and Europe’s technological sovereignty going forward”.
ABOUT INFRAVIA CAPITAL PARTNERS
InfraVia is an independent investment firm specialized in infrastructure. Founded in 2008by Vincent LEVITA, InfraVia focuses on European mid-market infrastructure and has done32 investments across 12 European countries since its creation. As at October 2019, the company employs 34 professionals and has €4bn of assets under management across 4 funds.
www.infraviacapital.com
ABOUT ALBAN WYNIECKI
• 13 years of experience in investment firms (Partech, Idinvest Partners) and tech (Dassault Système)• Leader on more than 25 investments and board member of several companies (Klaxoon, Lumapps, Platform.sh, Secret Escapes…)• Leader on more than 15 M&A transactions at 3DS (Gemqom, Accelrys, RTT…)• Graduated from ENS and HEC
ABOUT GUILLAUME SANTAMARIA
• 13 years of experience in tech investment and M&A (Quilvest, Apparius, Idinvest Partners)• Leader on more than 35 M&A and fund-raising transactions, in particular in digital health (BioSerenity, Mdoloris, H4D…). Board member of several companies (M2I, Adjust,SophiaGenetics…)• Graduated from Sciences Po Bordeaux and HEC
ABOUT FRANÇOIS AUQUE
• Former Chairman of the Investment Committee at Airbus Ventures• Former CEO of the Space Division at Airbus• Former CFO of Aerospatiale and Aerospatiale-Matra• 30 ans of experience in the industrial sector (Airbus, EADS, Aerospatiale-Matra,Aerospatiale …) and 8 years of experience in Finance (Credisuez, Banque La Henin,Cour des Comptes)• Chairman of the Audit and Risk Committee of Rexel, Board Member of CyberArk• Graduated from HEC, Sciences Po and ENA

Categories: News

Tags:

Francisco Partners completes the sale of ClickSoftware to Salesforce for $1.4 Billion Enterprise Value

Franciso Partners

San Francisco and London – Francisco Partners, a leading technology-focused global private equity firm, today announced it has completed the sale of ClickSoftware (“Click”) to Salesforce (NYSE: CRM) for an enterprise value of $1.4 billion. Francisco Partners took Click private in 2015.

Click is a leading provider of field service management solutions and optimization technology. The company arms field service professionals and mobile workers with innovative, AI-driven technologies and real-time schedule and route optimization at scale to improve their efficiency and effectiveness. Founded in 1997, Click is a pioneer in applying complex algorithms and artificial intelligence to workforce management and today helps manage over 1 million field resources around the world in a wide variety of industries including for organizations like Bosch, Deutsche Telekom and Unisys.

“Over the years, Click has built a leading product and a very strong market position. We are very proud to have been part of the company’s journey and wish all its employees continued success as part of Salesforce,” said Matt Spetzler, partner at Francisco Partners. “It has been a pleasure to partner with the Click team for these last four years and help them become a true global leader in Field Service Management,” commented Petri Oksanen, partner at Francisco Partners.

“The Click team has built an incredible company. We believe they are very well positioned for continued success as part of Salesforce,” added Mario Razzini, principal at Francisco Partners.

“Francisco Partners was a great partner for Click over the last few years,” said Mark Cattini, CEO of ClickSoftware. “Their strategic advice and the resources they contributed helped us improve many aspects of our business and accelerate revenue growth.”

“This is a fantastic outcome for ClickSoftware and Francisco Partners,” said Dipanjan Deb, Co-Founder and Chief Executive Officer of Francisco Partners. “Our investment in Click is a testament to our strategy of complexity arbitrage: we bought an orphaned public company, committed the full resources of the firm to improve the business across multiple dimensions, and ultimately sold to a strategic buyer.”

Goldman Sachs acted as the exclusive financial advisor and Paul Hastings acted as legal advisor to Francisco Partners.

About Francisco Partners

Francisco Partners is a leading global private equity firm that specializes in investments in technology and technology-enabled businesses. Since its launch 20 years ago, Francisco Partners has raised over $14 billion in committed capital and invested in more than 275 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit: www.franciscopartners.com

Categories: News

Tags:

Dyne Therapeutics announces appointment of Joshua Brumm as President and Chief Executive Office

Forbion

in portfolio news

Industry veteran brings extensive experience leading biotech companies through periods of growth.

WALTHAM, Mass.– Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Joshua Brumm as President and Chief Executive Officer.

“Josh brings extraordinary skills and experience to further our mission of creating life-transforming therapies for patients with serious muscle diseases,” said Jason Rhodes, partner with Atlas Venture and Dyne founder and executive chairman of the board of directors. “This positions us strongly to pursue the next phase of growth and product development, and we are thrilled to have him joining us.”

“Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Joshua Brumm. “I look forward to working closely with the board and talented team at Dyne to maximize the potential of our platform by advancing our pipeline and exploring new partnerships.”
“On behalf of everyone here, I am excited to welcome Josh,” said Romesh Subramanian, Dyne founder and chief scientific officer. “We look forward to working together to realize the therapeutic power of oligonucleotides for patients with rare muscle diseases and fulfilling Dyne’s mission.”

Prior to joining Dyne, Mr. Brumm served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Mr. Brumm has raised approximately $1 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame.

About Dyne Therapeutics
Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass.

For more information, please visit www.dyne-tx.com.
Media Contact Ten Bridge Communications Max Stendahl, 508-277-8117 max@tenbridgecommunications.com

Categories: People

Tags:

Divestiture of Aleris completed

Investor

Divestiture of Aleris completed Patricia Industries, a part of Investor AB, has following regulatory approval today completed the divestiture of Aleris to Triton. As announced on July 12, 2019, net cash proceeds are estimated to SEK 2bn. Following the completion of this divestiture, Patricia Industries no longer retains any ownership in Aleris. Doktor24, remains within Patricia Industries’ Financial Investments.

For further information:

Viveka Hirdman-Ryrberg, Head of Corporate Communication and Sustainability Phone +46 70 550 3500 viveka.hirdman-ryrberg@investorab.com

Magnus Dalhammar, Head of Investor RelationsPhone +46 735 24 2130 magnus.dalhammar@investorab.com

Our press releases can be accessed at www.investorab.com Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include among others ABB, Atlas Copco, Ericsson, Mölnlyckeand SEB. Investor AB Arsenalsgatan 8C, SE-103 32 Stockholm, Sweden+46 8 614 20 00 www.investorab.com

Categories: News

Tags:

The Carlyle Group Launches Boru Energy With Oil Industry Veterans Aidan Heavey and Tom Hickey

Carlyle

Boru Energy will target acquisitions of up to $1 billion, focussing on oil and gas opportunities across Sub-Saharan Africa

LONDON – Global investment firm, The Carlyle Group (NASDAQ:CG), announced today that it has agreed to partner with Aidan Heavey and Tom Hickey, through Boru Energy, a new platform that will target acquisitions of oil & gas assets across Sub-Saharan Africa. Aidan Heavey and Tom Hickey are well-regarded industry veterans with extensive investment experience investing in African oil & gas assets.

Boru Energy’s investment goal will be to assemble a portfolio of primarily non-operated interests in oil & gas production assets. The potential portfolio will be spread across several Sub-Saharan Africa countries and will consist of assets with significant commercialisation potential and where the operator is a high quality national, international or independent oil and gas company.

Funding for potential investments will come from Carlyle International Energy Partners, L.P. (CIEP), a fund that focuses on oil and gas exploration & production, midstream, and refining and marketing in Europe, Africa, Latin America and Asia. CIEP first invested in Africa in 2017, when Carlyle-backed Assala Energy acquired Shell’s onshore assets in Gabon. Boru Energy will benefit from the strong experience and industry expertise Carlyle has in this region and globally. This investment is led by Managing Director and Head of CIEP Marcel van Poecke and Managing Director Bob Maguire.

Aidan Heavey is the founder and former Chairman and CEO of Tullow Oil PLC, an Africa-focused exploration and production company listed on the London Stock Exchange. Under Heavey’s leadership, Tullow grew into a FTSE 100 company with production of over 80,000 barrels of oil equivalent per day. Tom Hickey was CFO of Tullow Oil between 2000 and 2008, where he worked closely with Mr Heavey, and has since held various management positions in the oil & gas industry.

Marcel van Poecke, Managing Director, and Head of the CIEP team, said: “Carlyle are pleased to partner with Aidan Heavey and Tom Hickey, both of whom have proven track records of successfully growing significant energy investments.  We look forward to providing them with support and capabilities in order to help Boru Energy as it builds a successful platform for investing in oil & gas opportunities across Sub-Saharan Africa.”

Aidan Heavey commented: “Boru Energy will build on our team’s experience and commitment to investing in Africa.  We will seek to invest to secure and increase production levels, extend field life cycles and support partners and governments to achieve long term, sustainable growth and create value.  We are committed to achieving best-in-class safety, environmental, social performance and transparent stakeholder partnerships. We look forward to working with Carlyle, future industry partners and our team on this exciting opportunity.”
For More Information:

The Carlyle Group:
Rory Macmillan
Roderick.Macmillan@carlyle.com
+44 (0) 207 894 1630

 

About the Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $223 billion of assets under management as of June 30, 2019, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,775 people in 33 offices across six continents. www.carlyle.com

About Carlyle’s Energy Platform

Carlyle has constructed a broad-based global energy, natural resources and infrastructure platform (currently with $27 billion in assets under management and 95 active portfolio companies), consisting of International Energy, North American Energy, North American Power and Global Infrastructure.

About CIEP

Established in May 2013, the CIEP team focuses on oil and gas exploration and production mid- & downstream, refining and marketing and oil field services in Europe, Africa, Latin America and Asia. The CIEP team focuses on transactions where it has a distinctive competitive advantage and can create tangible value for companies in which it invests, through industry specialization, deployment of human capital and access to The Carlyle Group’s global network. The team operates primarily from offices in London while leveraging Carlyle’s local offices to pursue opportunities across Europe, Africa, Asia and Latin America and is reinforced by The Carlyle Group’s regional fund teams and global investment professionals.

The CIEP team consists of 16 investment professionals, all with extensive international oil and gas industry investment and operational expertise. In addition to Marcel van Poecke, it includes Managing Directors Bob Maguire and Joost Dröge, both industry veterans with 55 years’ combined successful energy investing experience, as well as Paddy Spink, Senior Advisor to CIEP, with 35 years’ upstream experience in Africa, Latin America & Europe.

About Aidan Heavey

During his 33-year tenure at Tullow, Heavey developed Tullow into a company that maintains 80 exploration and production licenses in 15 countries in South America and Africa. Tullow is listed on the London, Irish, and Ghana Stock Exchanges. In 2017, Heavey stepped down as CEO of Tullow; however, he remained chairman until July 2018.

Tullow expanded in the 2000s through a series of acquisitions, most prominently the acquisition of Energy Africa in 2004, which doubled the company’s size by expanding Tullow’s production and exploration capabilities across Africa. In 2007, Tullow discovered and began production at the Jubilee oilfield—one of the largest oilfields in Africa—off the coast of Ghana. The company has continued to grow and had an exploration success rate of 70 percent, most recently offshore Guyana.

About Tom Hickey

Tom Hickey is an experienced oil & gas executive with more than 20 years of experience, including more than 10 years serving as a CFO at oil and gas exploration and production companies. From 2000 to 2008, Hickey was the CFO of London-headquartered E&P company Tullow. While at Tullow, Hickey oversaw the company’s USD 1.1 billion acquisition of Hardman Resources in 2007 and USD 570 million acquisition of Energy Africa in 2004. From 2011 to 2016, Hickey served as the corporate development officer and CFO of the Dublin-headquartered oil and gas exploration and production company PetroCeltic International PLC.

Categories: News

Tags:

Mainstay Medical announces acceptance for filing by US FDA of Pre-Market Approval (PMA) Application for ReActiv8

Capricorn

Dublin, Ireland: 1 October 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth of Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, today announces that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Pre-Market Approval (PMA) application for ReActiv8.

Mainstay submitted the PMA to the FDA in August. Per regulation, the FDA will notify the applicant whether the PMA has been accepted for filing within 45 days after submission. By accepting the Company’s PMA for filing, the FDA has made a threshold determination that the application is sufficiently complete to begin an in-depth review. Mainstay continues to expect a decision on approval around the end of 2020.

More information on Mainstay’s website.

 

Categories: News

Tags:

AURELIUS closes acquisition of BT Fleet Solutions from BT Group Plc

Aurelius Capital

  • Acquisition of the UK’s #1 commercial fleet management business delivering a comprehensive suite of services to blue chip customers, via its national network completed
  • Recent contract wins worth GBP 43 million
  • UK continues to be an attractive market for AURELIUS

Munich / London, 1. October 2019 – AURELIUS Equity Opportunities SE & Co. KGaA (ISIN DE000A0JK2A8) has completed the acquisition of industry leading end-to-end commercial fleet management operator, BT Fleet Solutions from BT Group Plc, with effect from 30 September 2019.

Headquartered in Solihull, BT Fleet Solutions offers a comprehensive suite of fleet management services across all stages of the vehicle life cycle, through its network of 65 in-house garages, 500 partner facilities and 50+ mobile technicians. Established in 2002, BT Fleet Solutions employs around 950 staff around the UK, and manages more than 80,000 vehicles for over 26 blue chip customers across diversified industries. The latest published statutory accounts for 2017/18 for BT Fleet Ltd show revenues of GBP 209.5 million and its industry leading position leaves it well placed to capture the high levels of growth available in the UK’s fleet management market.

BT Fleet Solutions has recently signed two significant contract wins, as follows:

  • A 5+2 year contract with construction company Kier Group to manage all passenger and commercial vehicle fleet services on an outsourced basis, including vehicle maintenance, accident management and invoice management. The contract is due to go live in December 2019 with a value of GBP 39 million to BT Fleet Solutions.
  • A 30-month contract with Highways England to provide fleet maintenance and management services to its fleet of around 420 vehicles. The contract value to BT Fleet Solutions is GBP 4 million.

“We see substantial growth potential for BT Fleet in the British market and we are looking forward to realizing this potential together with the company’s management and team,“ said Dr. Dirk Markus, Chief Executive Officer of the AURELIUS Group. “The United Kingdom will continue to be an attractive market for us in the future as well. Brexit and the related uncertainty are creating special opportunities from which investors like us can benefit.“

The divestment of BT Fleet Solutions aligns with BT’s ongoing transformation programme and strategy of focusing on converged connectivity and services, with further investments in both its fixed and mobile networks via programmes such as full fibre and 5G.
This deal represents another example of AURELIUS’ specialism in complex divestment processes. In the coming months, AURELIUS’ operational task force will support BT Fleet Solutions in executing a carve out from BT, ensuring a seamless continuation of the company’s day to day operations, whilst working to position the business as an independent entity. The company is expected to be rebranded within the next 12 months.

 

Categories: News

Tags:

Avedon Capital Partners expands team with appointment of Willem van der Veer

Avedon

Categories: People

Apiary Capital appoints new Investment Manager

Apiary Capital

Team-Jess.jpg

Apiary Capital is pleased to announce the appointment of Jessica French as Investment Manager.

Jess joins Apiary from boutique investment bank, Financo, having previously spent eight years at PwC, primarily in Corporate Finance advisory.

Jess’s appointment follows the successful close of Apiary’s £200m maiden fund last year, and the subsequent completion of the G3 Comms, Connect and Bertram Nursery Group investments earlier this year.

Mark Salter, Managing Partner at Apiary Capital commented, “Jess’s addition provides depth and breadth to our investment capability and we are delighted to welcome her to the Apiary team.”

Categories: People

n2 Biomedical Appoints Victor Nunes and Dean Schauer to Board of Directors

Bedford, MA – September 30, 2019: N2 Biomedical, a leading provider of proprietary surface treatment solutions and nanoscale coatings for implantable medical devices, today announced the appointments of Victor (“Vic”) Nunes and Dean Schauer to the Company’s Board of Directors. Nunes and Schauer join the Board following Ampersand Capital Partners’ majority recapitalization of the Company earlier this year. The transaction with Ampersand provided N2 Biomedical with an equity investment to fuel organic growth, expand the Company’s capabilities, and increase commercial sales efforts.

Mr. Nunes has over 25 years of medical device industry experience. He has served in a number of senior management and advisory roles in various medical device and life sciences companies, with a particular emphasis on orthopedics. Previous experience includes a variety of roles within DePuy Orthopedics, where he led integration of the $21 billion Synthes acquisition and assisted in the integration of DePuy Ace into Johnson & Johnson. Mr. Nunes also held Board positions at the Depuy Mitek and Codman Neuro divisions of J&J during his tenure as Senior Operations Executive. He has received advanced certifications from Duke University, the University of Virginia, and the University of Pennsylvania.

Mr. Schauer has served as President and CEO of Ampersand portfolio company Confluent Medical Technologies since 2013, and also joined Ampersand as an Operating Partner in 2016. Prior to Confluent, Mr. Schauer held a variety of executive leadership roles at Accellent, and was most recently Executive Vice President and General Manager of Accellent’s Cardiovascular Business. Prior roles at Accellent and its predecessors included EVP of Operations and Engineering, EVP of Sales and Marketing, and VP of Quality. Mr. Schauer holds a B.S. in Metallurgical Engineering from South Dakota Tech and is trained in Six Sigma methodology.

“Both Vic and Dean are proven, experienced executives within the medical device industry, and bring valuable insight to N2’s evolving growth strategy,” said Randall Sword, CEO of N2 Biomedical. “The additions to our Board come at an exciting time for N2 as we look to expand our service offering within medical end-markets. We welcome Vic and Dean’s experiences and guidance as we continue to build N2.”

About N2 Biomedical

Established in 2013, N2 provides coating and surface treatment development and application services for implantable and other medical devices utilized in orthopedic, cardiovascular, and other healthcare end-markets. N2 is ISO-13485 certified, FDA GMP-compliant, and operates in a 30,000 square foot facility with laboratory, manufacturing, and cleanroom space to service all customer and regulatory requirements. The company leverages its proprietary processes and equipment to provide customized solutions that enhance the characteristics of various materials in critical applications, including lubricity, infection resistance, biocompatibility and tissue integration, and wear and corrosion resistance. Additional information about N2 Biomedical is available at N2bio.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at ampersandcapital.com.

Categories: People